Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2020
Historique:
received: 03 02 2020
accepted: 20 05 2020
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 25 8 2020
Statut: epublish

Résumé

A unique glycoprotein is expressed on the virus envelope of human herpesvirus 6B (HHV-6B): the complex gH/gL/gQ1/gQ2 (hereafter referred to as the HHV-6B tetramer). This tetramer recognizes a host receptor expressed on activated T cells: human CD134 (hCD134). This interaction is essential for HHV-6B entry into the susceptible cells and is a determinant for HHV-6B cell tropism. The structural mechanisms underlying this unique interaction were unknown. Herein we solved the interactions between the HHV-6B tetramer and the receptor by using their neutralizing antibodies in molecular and structural analyses. A surface plasmon resonance analysis revealed fast dissociation/association between the tetramer and hCD134, although the affinity was high (KD  = 18 nM) and comparable to those for the neutralizing antibodies (anti-gQ1: 17 nM, anti-gH: 2.7 nM). A competition assay demonstrated that the anti-gQ1 antibody competed with hCD134 in the HHV-6B tetramer binding whereas the anti-gH antibody did not, indicating the direct interaction of gQ1 and hCD134. A single-particle analysis by negative-staining electron microscopy revealed the tetramer's elongated shape with a gH/gL part and extra density corresponding to gQ1/gQ2. The anti-gQ1 antibody bound to the tip of the extra density, and anti-gH antibody bound to the putative gH/gL part. These results highlight the interaction of gQ1/gQ2 in the HHV-6B tetramer with hCD134, and they demonstrate common features among viral ligands of the betaherpesvirus subfamily from a macroscopic viewpoint.

Identifiants

pubmed: 32678833
doi: 10.1371/journal.ppat.1008648
pii: PPATHOGENS-D-20-00217
pmc: PMC7367449
doi:

Substances chimiques

Receptors, OX40 0
TNFRSF4 protein, human 0
Viral Envelope Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008648

Déclaration de conflit d'intérêts

The authors declare no conflicts.

Références

Nat Struct Mol Biol. 2010 Jul;17(7):882-8
pubmed: 20601960
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22641-6
pubmed: 21149717
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9096-9
pubmed: 23674671
J Virol. 2011 Nov;85(21):11121-30
pubmed: 21849437
J Struct Biol. 2016 Jul;195(1):93-9
pubmed: 27108186
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6056-61
pubmed: 25918416
J Virol. 2002 Jul;76(13):6750-61
pubmed: 12050388
J Virol. 2004 May;78(9):4609-16
pubmed: 15078943
J Virol. 2019 May 1;93(10):
pubmed: 30842329
J Virol. 2003 Feb;77(4):2452-8
pubmed: 12551983
J Clin Microbiol. 1989 Apr;27(4):651-3
pubmed: 2542358
Lancet. 1988 May 14;1(8594):1065-7
pubmed: 2896909
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 2017 Mar 13;91(7):
pubmed: 28077654
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
J Virol. 2015 Oct;89(19):10125-9
pubmed: 26202244
Clin Infect Dis. 2013 Sep;57(5):671-81
pubmed: 23723198
Gene. 1991 Dec 15;108(2):193-9
pubmed: 1660837
Cell Microbiol. 2009 Jul;11(7):1001-6
pubmed: 19290911
PLoS Pathog. 2014 Aug 21;10(8):e1004309
pubmed: 25144748
Curr Opin Virol. 2017 Jun;24:97-104
pubmed: 28538165
Adv Exp Med Biol. 2018;1045:227-249
pubmed: 29896670
J Virol. 2004 Aug;78(15):7969-83
pubmed: 15254169
J Neurovirol. 2017 Feb;23(1):1-19
pubmed: 27538995
J Virol. 2015 May;89(9):5159-63
pubmed: 25694589
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8703-E8710
pubmed: 28939750
Virology. 1990 Jun;176(2):625-8
pubmed: 2161152
Curr Opin Virol. 2016 Jun;18:1-8
pubmed: 26849495
Nat Microbiol. 2016 Jun 06;1(8):16082
pubmed: 27573107
Bone Marrow Transplant. 2015 Aug;50(8):1030-6
pubmed: 25915811
Sci Immunol. 2017 Jun 30;2(12):
pubmed: 28783665
J Virol. 2011 Dec;85(24):12962-71
pubmed: 21957287
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Arch Virol. 2014 May;159(5):863-70
pubmed: 24193951
Biol Blood Marrow Transplant. 2012 Nov;18(11):1638-48
pubmed: 22564265
Cell. 2018 Aug 23;174(5):1158-1171.e19
pubmed: 30057110
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
J Struct Funct Genomics. 2006 Mar;7(1):15-22
pubmed: 16645781
Cell. 1999 Dec 23;99(7):817-27
pubmed: 10619434
Structure. 2006 Aug;14(8):1321-30
pubmed: 16905106
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
N Engl J Med. 1994 Aug 18;331(7):432-8
pubmed: 8035839
J Virol. 2014 Sep;88(18):10875-82
pubmed: 25008928
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J Exp Med. 2004 Feb 16;199(4):525-33
pubmed: 14970179
Nat Commun. 2016 Dec 08;7:13557
pubmed: 27929061
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1767-72
pubmed: 25624487
J Gen Virol. 1997 Sep;78 ( Pt 9):2171-8
pubmed: 9292004
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Mitsuhiro Nishimura (M)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Bernadette Dian Novita (BD)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Department of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, Indonesia.

Takayuki Kato (T)

Protonic NanoMachine Group, Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan.

Lidya Handayani Tjan (L)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Bochao Wang (B)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Aika Wakata (A)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Anna Lystia Poetranto (A)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Akiko Kawabata (A)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Huamin Tang (H)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Taiki Aoshi (T)

Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Osaka, Japan.

Yasuko Mori (Y)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH